Patent · US Active

Combination therapies

US10980774B2 · kind B2 · utility

1Cited by

62References

6Claims

0Family size

Assignees

MEI PHARMA, INC. · US
The Spanish National Cancer Research Centre · ES

Inventors

Daniel P. Gold · Del Mar, US
Miguel Quintela-Fandino · Madrid, ES

Key dates

Filing date	Feb 1, 2016
Grant date	Apr 20, 2021
Priority date	—
Expiry date	Feb 11, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.